Oncology drugs Flashcards
1
Q
Filgrastim
A
Neuopgen, Zarxio
2
Q
Pegfilgrastim
A
Neulasta
3
Q
Aprepitant
A
Emend
4
Q
Fosaprepitant
A
Emend (injection only), dosed one time
5
Q
Ondansetron
A
Zofran
6
Q
Granisetron
A
Sancuso
7
Q
Dolasetron
A
Anzemet
8
Q
Palonosetron
A
Aloxi
9
Q
Palonosetron + netupitant
A
Akynzeo
10
Q
Dexamethasone
A
Decadron
11
Q
Prochlorperazine
A
Compazine
12
Q
Promethazine
A
Phenergan
13
Q
Metoclopramide
A
Reglan
14
Q
Dronabinol
A
Marinol
15
Q
Nabilone
A
Cesamet
16
Q
Mucsal Barrier Gel Spray
A
Episil, Gelclair
17
Q
Artificial Saliva Substitutes
A
Aquora, Biotene
18
Q
Pilocarpine
A
Salagen
19
Q
Calcitonin
A
Miacalcin
20
Q
Zoledronic acid
A
Zometa
21
Q
Denosumab
A
Xgeva
22
Q
Tamoxifen
A
Soltamox (SERM)
23
Q
Fulvestrant
A
Faslodex (SERM)
24
Q
Anastrozole
A
Arimidex (Aromatase inhibitor)
25
Letrozole
Femara (Aromatase inhibitor)
26
Exemestane
Aromasin (Aromatase inhibitor)
27
Leuprolide
Lupron Depot (GnRH agonist)... osteoporosis + tumor flare
28
Goserelin
Zoladex (GnRH agonist)... osteoporosis + tumor flare
29
Degarelix
Firmagon Gonadotropic releasing hormone antagonist
30
Bicalutamide
Casodex (First generation antiandrogen)
31
Enzalutamide
Xtandii (Second generation antiandrogens)
32
Cyclophosphamide
Cytoxan (alkylating agent)
33
Carmustine
BiCNU (alklylating agent)
34
Bendamustine
Bendeka (alkylating agent)
35
Busulfan
Myleran (alkylating agent)
36
Melphalan
Alkeran (alkylating agent)
37
Cisplatin
nephrotoxic, ototoxic (confirm doses >100 mg/m2/cycle with prescriber)
38
Carboplatin
Calvert formula: dose = (target AUC) x (GFR + 25) [AUC range from 2-8 mg/ml*min) (GFR commonly capped at 125 ml/min)
39
Oxaliplatin
acute sensory neuropathy, cold
40
Doxorubicin
Adriamycin (Anthracycline, total cumulative dose 450-550 mg/m2)
41
Dexrazoxane
Totect, used for anthracycline extravasation; Zinecard for cardioprotection
42
Mitoxantrone
anthracenedione related to anthracyclines; blue urine discoloration
43
Vincristine
Vincasar (vinca alkaloid), intrathecal = death
44
Vinblastine
myelosuppressive, less neurotoxic
45
Paclitaxel
Taxol (Taxane) (peripheral sensory neuropathy)
46
Docetaxel
Taxotere (Taxane)
47
Cabazitaxel
Jevtana (Taxane)
48
Paclitaxel albumin-bound
Abraxane (no premedication required)
49
Irinotecan
Camptosar (topoisomerate I inhibitor (acute cholinergic symptoms, delayed diarrhea)
50
Etoposide
VePesid (Topoisomerase II inhibitor)
51
Fluorouracil
Adrucil, 5-FU (Pyrimidine analog antimetabolites)
52
Capecitabine
Xeloda (Oral prodrug of fluorouracil)
53
Methotrexate
Trexall [folate antimetabolite] (drug interaction with NSAIDs, csalicylates, beta-lactams, PPI, sulfanoamide antibiotics --> decrease clearance of methotrexate)
54
Pemetrexed
Alimta (folate antimetabolite, related to methotrexate)
55
Tretinoin
All-trans retinoic acid (used in acute promyelocytic leukemia), decreases proliferation and increases differentiation
56
Arsenic trioxide
Trisenox (QT prolongation)
57
Asparaginase
Erwinaze, deprives leukemia cells of essential amino acid asparagine
58
Pegaspargase
Oncaspar (pegylated form of asparaginase allows less frequent dosing and less allergic reactions)
59
Bleomycin
Not myelosuppressive, lifetime dose of 400 units due to pulmonary toxicity
60
Mitomycin
Vesicant, antidote is dimethyl sulfoxide (cool compress)
61
Everolimus
Afinitor - for cancer
| Zortress - for transplant
62
Lenalidomide
Revlimid (immunomodulator used in multiple myeloma, severe birth defects)
63
Pamilidomide
Pomalyst (immunomodulator used in multiple myeloma. severe birth defects.)
64
Thalidomide
Thalomid (immunomodulator used in multiple myeloma. severe birth defects)
65
Bortezomib
Velcade (proteasome inhibitor - antiviral can prevent herpes reactivation)
66
Carfilzomib
Kyprolis (peripheral neuropathy)
67
Bevacizumab
Avastin (VEGF innibitor), delayed wound healing
68
Ramucirumab
Cyramza (VEGF inhibitor) delayed wound healing
69
Trastuzumab
Herceptin (Human epidermal growth factor receptor 2 HER2 inhibitors), cardiotoxicity, embryo-fetal toxicity
70
Pertuzumab
Perjeta (Human epidermal growth factor receptor 2 HER2 inhibitors), cardiotoxicity, embryo-fetal toxicity
71
Ado-trastuzumab Emtansine
Kadcycla (Human epidermal growth factor receptor 2 HER2 inhibitors), cardiotoxicity, embryo-fetal toxicity
72
Cetuximab
Erbitux (Epidermal Growth Factor Receptor EGFR inhibitor), cardiac arrest; rash + sun sensitivity
73
Panitumumab
Vectibix (EGFR inhibitor) dermatologic toxicities
74
Rituximab
Rituxan (Leukocyte Cluster of Differentiation (CD) Antigen Inhibitors , Rituxmab is CD20; premedicate for infusion reactions; must be CD20 positive to use
75
Blinatumomab
Blincyto (Leukocyte Cluster of Differentiation CD19 and CD3 inhibitor)
76
Pembrolizumab
Keytruda (PD-1 inhibitor -> blocks the binding of the Programmed cell death ligand from binding PD-1 receptor on T cells, which allows T-cells to live longer and attack cancer)
77
Nivolumab
Opdivo (PD-1 inhibitor)
78
Ipilimumab
Yervoy (Cytotoxic T-Lymphocyte Antigen-4 CTLA-4 inhibitor)
79
Common Toxicities of Tyrosine Kinase Inhibitors (Hint: thyroid, heart, skin, blood vessels, intestines, liver)
1. Thyroid gland: Hypothyroidism
2. Heart: QT Prolongation
3. Skin: EGFR TKI cause severe acienform rash that is correlated with efficacy
4. TKI that target vascular endothelial growth factor: Hand-foot syndrome and hypertension (interference with growth of blood vessels)
5. large intestine: diarrhea
6. liver: hepatic metabolite (CYP3A4 substrate); hepatic toxicity
